Arg-BPC-157

BPC-157 Arginine Salt · BPC-157 Arginate · Oral BPC-157 · "Pentadeca Arginate" (PDA)

"BPC-157 re-formulated as an arginine salt for oral stability. While standard BPC-157 is unstable in stomach acid (degraded within minutes), the arginine salt form survives gastric passage and reaches the small intestine intact. Growing rapidly in adoption since the 2025 FDA Category 1 reclassification made compounding pharmacy access to BPC-157 legitimate."

Type

BPC-157 arginate salt · oral-stable form

vs Standard BPC-157

Survives gastric pH · oral instead of injection

Status

UK: not illegal to buy or possess · WADA: not specifically listed · US FDA: Category 1 compoundable (2025 reclassification) · no direct arginate-form RCTs · inherits BPC-157 mechanism data

Mechanism

Same as BPC-157 · VEGFR2 · growth factors

Protocol summary

Community dose

250–500 mcg oral · 1–2× daily

Course

4–8 weeks · then break

Best use case

Gut healing · GI applications

Community-reported

250–500 mcg oral · 1–2× daily · 4–8 week cycles · gut-healing applications preferred

"7-fold bioavailability" marketing claims significantly exceed published evidence; no peer-reviewed trials specifically on the arginate form

How we read the evidence

Arginate salt of BPC-157 marketed as "Pentadeca Arginate" (PDA) · oral-bioavailability marketing claims significantly exceed published evidence · zero peer-reviewed trials specifically on the arginate form · standard BPC-157 evidence does NOT automatically transfer

Animal evidence

Important framing: the substantial preclinical evidence for BPC-157 was almost exclusively conducted with the acetate salt form, not the arginate. When vendors cite 'BPC-157 research' for PDA, they are referencing work done with a different salt. Sikiric's group's animal studies — gastric ulcer protection, tendon healing, vascular work — used the acetate. The arginate form was developed specifically as an oral-stability strategy. The patent demonstrates gastric stability (peptide survives stomach acid) — that is a precondition for oral absorption but is NOT the same as proving oral bioavailability. Whether the intact peptide crosses the intestinal lining at the claimed rates has not been measured in any peer-reviewed publication.

Community & clinical practice

Standard community use is oral capsules at 250 mcg or 500 mcg per capsule, typically once or twice daily for 4–8 week courses. Marketed primarily by US compounding pharmacies and research vendors as 'Pentadeca Arginate (PDA)' or 'BPC-157 Arginate'. The '7-fold bioavailability increase' claim is unsubstantiated — it cannot be traced to any published study or even to the patent itself. Some vendors also claim the arginine counter-ion provides additional nitric oxide benefits; at the molar concentrations present in a 500 mcg peptide dose, the arginine contribution is pharmacologically trivial. Members using BPC-157 for systemic effects (recovery, anti-inflammatory, repair) generally see better-validated outcomes with the acetate form via SubQ injection, where the substantial preclinical evidence base actually applies. The arginate form's specific use case is oral GI-targeted dosing where local gut effects are the goal.

Human trial data

Zero peer-reviewed publications exist on Pentadeca Arginate specifically. A PubMed search for 'pentadeca arginate' returns no results. The compound is marketed under the assumption that all BPC-157 acetate evidence transfers automatically — but salt forms can affect pharmacokinetics, distribution, and tissue uptake in ways that change clinical effects, and no comparative bioavailability or efficacy study has been published. The closest evidence is the gastric-stability patent, which addresses a different and narrower question. Standard BPC-157 (acetate) itself has no published Phase 3 human trials despite decades of preclinical work — see the BPC-157 entry on this platform — so PDA inherits the parent compound's evidence gap PLUS adds a salt-form translation gap on top.

Regulatory status

Not approved by any regulatory agency. Available primarily through US 503A/503B compounding pharmacies that market PDA as a distinct compound. The 'arginate' framing has been used by some pharmacies to position PDA as a regulatory-cleaner alternative to BPC-157 — this distinction is more marketing than substance. Both are non-approved research peptides. WADA-banned via the parent compound's listing.

Convergence

Pentadeca Arginate is BPC-157 in an arginine salt form, marketed primarily for oral use. The marketing claims significantly exceed what is published: the '7-fold bioavailability increase' and '90% oral bioavailability' figures cannot be traced to peer-reviewed studies or even the underlying patent. The arginate counter-ion at typical peptide doses is pharmacologically negligible as a nitric-oxide source. Pep IQ flags this honestly: members considering PDA should understand that (1) zero peer-reviewed trials exist on this specific form, (2) the parent BPC-157 acetate's evidence is itself preclinical-only, and (3) the salt-form translation is unvalidated. For systemic effects, SubQ acetate is the better-evidenced choice; the arginate's narrow plausible niche is gut-targeted oral dosing where local GI effects are the goal. Marketing claims should be read with significant scepticism.

Origin & Background

BPC-157 without the needle

Standard BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective protein in human gastric juice. Its remarkable healing and regenerative properties have made it one of the most popular peptides in the community. The challenge: standard BPC-157 acetate salt is unstable in the acidic environment of the stomach and is rapidly degraded by gastric proteases before it can be absorbed from the small intestine. This is why SubQ or intramuscular injection has been the dominant delivery route for systemic effects.

Arg-BPC-157 — the arginine salt form — addresses this by forming an ionic complex with arginine that significantly improves acid stability. The arginine salt maintains the peptide structure at stomach pH (1.5–3.5), enabling it to survive gastric transit and reach the small intestine where absorption occurs. This transforms BPC-157 from an inject-only compound to an oral capsule that non-injecting users can practically use.

Adoption has accelerated sharply since early 2025, when RFK Jr. announced that BPC-157 would be returned to the FDA Category 1 list for compounding pharmacies — meaning compounding pharmacies can legally prepare and dispense BPC-157 formulations including oral Arg-BPC-157 capsules. This legitimised access has shifted many users from research chemical injection peptides to pharmacy-compounded oral formulations, significantly expanding the addressable audience.

For the complete BPC-157 mechanism, evidence base, and community evidence, see the BPC-157 entry in Part One. Arg-BPC-157 shares all the same biology — VEGFR2 upregulation, angiogenesis, growth factor expression, gut healing, musculoskeletal repair. This entry focuses on the oral delivery distinction, dosing differences, and practical comparison to injectable BPC-157.

Science & Mechanism

The arginine salt — surviving the stomach

Mechanism of Action

Acid stability via arginine salt formation: Arginine (pKa ~10.5) forms an ionic salt with BPC-157 that buffers the peptide at gastric pH. The arginine nitrogen remains protonated at stomach pH, protecting adjacent peptide bonds from protonation-assisted hydrolysis and reducing the rate of acid-catalysed degradation. The complex dissociates in the near-neutral pH of the small intestine, releasing free BPC-157 for absorption.

Intestinal absorption and systemic distribution: Once in the small intestinal lumen, BPC-157 is absorbed via peptide transport (PepT1) and possibly transcellular routes, reaching portal circulation and then systemic distribution. Given that BPC-157 was isolated from gastric juice and is naturally present in the GI tract, the gut epithelium and submucosal tissue are likely the most efficiently targeted tissues following oral administration.

Gut-specific vs systemic effects: The strongest case for oral Arg-BPC-157 over injectable BPC-157 is in gut healing applications: leaky gut, IBD, SIBO, mucosal repair. The peptide reaches the intestinal wall at high local concentrations before systemic distribution, maximising the gut-healing signal. For systemic musculoskeletal applications (tendon, ligament, cartilage repair), injectable BPC-157 may still deliver better concentrations to non-GI tissues.

Same downstream mechanism: At the receptor level, Arg-BPC-157 activates the same VEGFR2-dependent angiogenesis, FAK-paxillin cell migration, and growth factor upregulation (VEGF, EGF, FGF) as injectable BPC-157. The arginine modification is a delivery vehicle change, not a pharmacodynamic change.

Dosing differences: Oral bioavailability is lower than SubQ injection due to incomplete intestinal absorption. Community experience suggests oral Arg-BPC-157 doses of 500mcg-1mg are needed to achieve effects comparable to 250-500mcg injectable BPC-157. Higher doses compensate for the absorption deficit.

Things to know

Safety — inherits BPC-157 profile

Mild

GI effects at high doses -- loose stools or mild nausea at doses above 1mg in some users. Start at 250-500mcg and titrate. Generally resolves within the first week.

Mild

Arginine effects -- arginine at high doses can stimulate nitric oxide production and cause mild blood pressure lowering. At the doses used as a BPC-157 delivery vehicle (equimolar arginine), this is not clinically significant for most people.